Circuit dysfunction is clearly recognized as a driver of neuropsychiatric disease, and some neurodegenerative diseases such as Parkinson’s disease. And at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2022 Congress, researchers made an argument that the same is true in multiple sclerosis (MS). Such a lens could explain the radiological-clinical paradox between the amount of structural damage and clinical severity. Read More
Nowadays, there are many tools for cancer diagnosis, from imaging techniques to biopsies. In traditional blood tests, liquid biopsy bursts onto the scene as an explosion of possibilities driven by molecular techniques for the detection and sequencing of proteins or genetic material. But specialists are cautious because they know that in liquid biopsies not everything is detected. At the ENA 2022 session “The role of ctDNA in clinical trials,” Marie Morfouace, a translational researcher at the EORTC, presented “ctDNA in clinical trial practice today,” where she described the balance of the possibilities of the liquid biopsy when confronting it with the results in patients offered by the studies published to date. Read More
CSPC Pharmaceutical Group Ltd. announced that the National Medical Products Administration of the People’s Republic of China has granted approval to conduct clinical trials of the company’s antibody-drug conjugate candidate, SYS-6002. Read More
Kancera AB has reported new preclinical data for its ROR1 inhibitor KAN-571, being developed for the treatment of mantle cell lymphoma (MCL). Read More
Genfleet Therapeutics Inc. has divulged amine-substituted pyridine fused-ring compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer. Read More
Pfizer Inc. has divulged 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19). Read More
Simcere Pharmaceutical Group announced that the FDA has cleared the company’s IND application for SIM-0237 for the treatment of adult patients with advanced solid tumors. Read More
Arbutus Biopharma Corp. has described programmed cell death 1 ligand 1 (PD-L1) antagonists reported to be useful for the treatment of cancer, hepatitis B and hepatitis D viral infection. Read More
Nerviano Medical Sciences Srl has synthesized substituted pyrrole carboxamides acting as cell division cycle 7-related protein kinase (CDC7) inhibitors reported to be useful for the treatment of cancer. Read More
Investigators working at the Jiangxi Science & Technology Normal University, China, have reported the development of novel ruthenium polypyridine antibiotics with demonstrably promising in vitro and in vivo activity against Staphylococcus aureus. Read More
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently bonded to estrogen receptor-α (ERα)-targeting moiety through a linker reported to be useful for the treatment of breast cancer and infections. Read More
Additional early-stage research and drug discovery news in brief, from: Aadi Bioscience, Promontory Therapeutics, Salarius Pharmaceuticals, Vaccitech. Read More
